Data have shown that breast cancer patients with high baseline levels of serum VEGF (≥367 ng/mL) are more responsive to any type of breast cancer treatment than patients with lower levels and that serum VEGF is an independent predictor of treatment response [24]. This evidence concerns the gene VEGFA and breast cancer.